Michael Alrutz
General Counsel bei CHIMERIX, INC.
Vermögen: 118 115 $ am 30.04.2024
Profil
Michael A.
Alrutz is currently the Secretary, Senior Vice President & General Counsel at Chimerix, Inc. He previously worked as the General Counsel at Trimeris, Inc. from 2002 to 2011.
He completed his undergraduate degree at the University of Pennsylvania, his graduate degree at Duke University School of Law, and his doctorate at the Sackler School of Graduate Biomedical Sciences.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CHIMERIX, INC.
0,15% | 31.03.2024 | 132 564 ( 0,15% ) | 118 115 $ | 30.04.2024 |
Aktive Positionen von Michael Alrutz
| Unternehmen | Position | Beginn |
|---|---|---|
| CHIMERIX, INC. | General Counsel | 01.06.2012 |
Ehemalige bekannte Positionen von Michael Alrutz
| Unternehmen | Position | Ende |
|---|---|---|
Trimeris, Inc.
 Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | General Counsel | 04.11.2011 |
Ausbildung von Michael Alrutz
| University of Pennsylvania | Undergraduate Degree |
| Duke University School of Law | Graduate Degree |
| Sackler School of Graduate Biomedical Sciences | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CHIMERIX, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Trimeris, Inc.
Trimeris, Inc. Pharmaceuticals: MajorHealth Technology Trimeris, Inc. develops therapeutics for viral diseases. It is a biopharmaceutical company engaged in the discovery, development and commercialization of novel therapeutic agents for the treatment of viral disease. The core technology platform of fusion inhibition is based on blocking viral entry into host cells. The company was founded in 1993 and is headquartered in Durham, NC. | Health Technology |
